Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEO 39652 cream in mild to moderate atopic dermatitis
NCT02219633Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- Jul 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing LEO 39652 cream with LEO 39652 cream vehicle (2 arms). Primary endpoint: Total sign score at end of treatment at 22 days. Started Jul 2014; status: completed.
02
Drugs
LEO 39652
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02219633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219633.